Conference Reports for NATAP

Back

HIV Research for Prevention (HIVR4P) October 17-19, 2016 Chicago     Use of Injectable Depot Medroxyprogesterone Acetate (DMPA) Downregulates Vaginal Epithelial Barrier Genes - Similarly to Mucosal Inflammation - (10/24/16)   Modulation of Tenofovir (TFV) Pharmacokinetics and Antiviral Activity by Vaginal Microbiota: Implications for Topical PrEP - (10/24/16)   Microbiome Composition & Function Drives Would-Healing Impairment in the Female Genital Tract - (10/24/16)   Genes Tied to Mucosal Injury/Repair in Rectum of MSM Having Receptive Anal Sex - Mark Mascolini - (10/24/16)   Tenofovir / IQP-0528 Combination Gel Effectively Inhibits HIV and Is Not Affected by Semen - (10/24/16)   Pre-exposure Prophylaxis with EFdA Offers Strong Protection against High Dose Mucosal HIV Challenges - [Long-Acting New NRTI for Treatment & PrEP] - (10/24/16)   Genes Tied to Mucosal Injury/Repair in Rectum of MSM Having Receptive Anal Sex - Mark Mascolini - (10/24/16)   Can we prevent HIV infection by focusing on the HIV target cell rather than the virus? Common Anti-inflammatory Medications Reduce HIV-Target Infection Cells Apparently Reducing Inflammation/Immune Activation & Creating "Immune Quiescence" - (10/21/16)   US Women in the HPTN 069/ACTG 5305 Phase II Maraviroc PrEP study: A substudy evaluating acceptability and experiences - (10/21/16)   Understanding Longitudinal HIV Care Trajectories to Improve Health and Reduce HIV Transmission in North Carolina - Sub Optimal - (10/21/16)   PrEP Knowledge and Use in San Francisco - 12,500 PrEP Users in SF - Lower use by African-Americans, age & Females - (10/21/16)   To switch or not to switch: anticipating choices in biomedical HIV prevention - from Oral to Long Acting Injectable PrEP - 90 Men using PrEP Surveyed - (10/21/16)   Are Ring Worries Affecting Use? Findings from the MTN-020/ASPIRE Phase III Dapivirine Ring Trial - (10/21/16)   In San Francisco 12,500 on PrEP--But Lower Use in Young, Blacks, Women - Mark Mascolini - (10/21/16)   HIV Mobile in Cervicovaginal Mucus of Women With Bacterial Vaginosis / Risk for HIV Aquisition - Mark Mascolini - (10/21/16)   Five HIV Care Trajectories Seen in 15,000-Person North Carolina Study..... Poor Engagement in Care - Mark Mascolini - (10/21/16)   Good Adherence by 58% of Women in Maraviroc PrEP Trial--But It Works - Mark Mascolini - (10/21/16)   Evaluation of MK-2048 and Vicriviroc, Formulated as Single or Combination (MK-2048A) Intravaginal Rings, for Development as a Vaginal Microbicide - (10/19/16)   Two Thirds of Oral PrEP-Using MSM Would Switch to Long-Term Shots - Mark Mascolini - (10/19/16)   Anal Sex May Explain One Third of New Heterosexually-Acquired HIV in Group of US Women - Mark Mascolini - (10/19/16)   Newly Acquired HIV-1 Infection with Multi-Drug Resistant HIV-1 in a Patient on TDF/FTC-based PrEP - (10/19/16)   Low-Dose Aspirin or Hydroxychloroquine Limits Activated Target Cells in Genital Tract - Mark Mascolini - (10/19/16)   Novel Integrase Mutation in Macaque Cabotegravir Study--But "Limited" Clinical Impact - Mark Mascolini - (10/19/16)   Low-Dose Aspirin or Hydroxychloroquine Limits Activated Target Cells in Genital Tract - Mark Mascolini - (10/19/16)   Infection With Multidrug-Resistant HIV While Adherent to TDF/FTC PrEP - Mark Mascolini - (10/19/16)   One Third of Women in US Study May Pick Up HIV During Anal Sex - Mark Mascolini - (10/19/16)